Comparison · NCT00377234-sae
Ibandronate vs Risedronate: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ibandronate vs Risedronate: serious adverse events. Trial comparisons, record NCT00377234-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00377234-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0153 | 0.00655 | 0.0353 | wilson | |
| Risk in group 2 | 0.00917 | 0.00312 | 0.0266 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00612 | -0.0134 | 0.027 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.67 | 0.402 | 6.92 | log | |
| Odds ratio, group 1 over group 2 | 1.68 | 0.397 | 7.08 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ibandronate than on Risedronate | 164 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ibandronate | Ibandronate adverse events | 5 | 327 | EG000 |
| Group 2 | Risedronate | Risendronate adverse events | 3 | 327 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Study duration was approximately 6 months (3 months and 12 weeks) and a follow-up period of 15 days after the completion of treatment was included to assess safety information. Participants were assessed for adverse events for a total of 6.5 months.
Source ClinicalTrials.gov
Trial
- Title
- A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
- NCT number
- NCT00377234
- Phases
- PHASE4
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- Risedronate, ibandronate [Bonviva/Boniva]
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2015-07-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00377234?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00377234-sae